FDA reviewing safety of Sanofi's Lantus insulin

Jul 01, 2009 By LINDA A. JOHNSON , AP Business Writer

(AP) -- The Food and Drug Administration said Wednesday it is reviewing data on the safety of Lantus, a synthetic insulin made by Sanofi-Aventis SA.

The move comes after a recent, widely publicized study raised the possibility the once-a-day slightly increases risk of cancer.

In a statement, the FDA said patients should not stop taking their insulin without consulting a doctor because of the risk of serious complications, both immediate and long term. Patients with and many with advanced must inject insulin at least once a day to control their blood sugar.

The agency said it is reviewing many sources of safety data for Lantus, including the new study.

Last Friday, the European Association for the Study of Diabetes said a review of an insurance database of 127,000 patients in four European countries found that out of every 100 patients using Lantus for about 1 1/2 years, one additional person developed cancer.

The association called the results inconclusive and urged further study of Lantus, known generically as insulin glargine.

Three of the four studies suggested an increased risk of various types of cancer, the FDA noted. It said the patients were not followed long enough to conclusively evaluate the risk.

"Further, inconsistencies in findings within and across individual studies raise concerns as to whether an association between the use of insulin glargine and cancer truly exists," the FDA said.

The agency said it is talking with Paris-based Sanofi-Aventis about whether additional safety and effectiveness studies will need to be done. The agency plans to disclose any findings as the review continues, and asked patients and doctors to report any side effects from use of Lantus to the FDA MedWatch Adverse Event Reporting Program.

Since the study results were disclosed, Sanofi-Aventis officials have been defending the safety of Lantus with a company statement, a conference call with analysts and a video message from the chief medical officer.

Other experts and some patient groups, including the American Diabetes Association, have urged to talk to their doctor rather than stopping use of Lantus.

It is the company's third-best-selling drug and a key growth driver, with revenue up 28 percent to nearly $3.5 billion last year.

In New York trading Wednesday, Sanofi shares rose $1.06, or 3.6 percent, to $30.55.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: India's meth addiction grows as criminals tap chemical hub

add to favorites email to friend print save as pdf

Related Stories

Insulin analogue glargine possibly increases cancer risk

Jun 26, 2009

The risk of cancer possibly increases if patients with diabetes use the long-acting insulin analogue glargine instead of human insulin. The Institute for Quality and Efficiency in Health Care (IQWiG), in collaboration with ...

FDA approves new diabetes treatment

Oct 17, 2006

The U.S. Food and Drug Administration has approved the use of Januvia tablets as the first in a new class of diabetes drugs.

FDA: Bristol-Myers diabetes drug appears safe

Mar 30, 2009

(AP) -- A potential blockbuster diabetes medication from Bristol-Myers Squibb appears free from heart-related side effects that have plagued similar treatments, federal health officials said Monday.

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments : 0